These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 18332041)

  • 21. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes.
    Zhang W; Zhou M; Lu W; Gong J; Gao F; Li Y; Xu X; Lin Y; Zhang X; Ding L; Zhang Z; Li G; Chen X; Sun X; Zhu X; Xu P; Zhang Y
    Theranostics; 2020; 10(7):3000-3021. PubMed ID: 32194851
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased expression of α-synuclein in aged human brain associated with neuromelanin accumulation.
    Xuan Q; Xu SL; Lu DH; Yu S; Zhou M; Uéda K; Cui YQ; Zhang BY; Chan P
    J Neural Transm (Vienna); 2011 Nov; 118(11):1575-83. PubMed ID: 21461961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects.
    Shehadeh L; Mitsi G; Adi N; Bishopric N; Papapetropoulos S
    Mov Disord; 2009 Jan; 24(2):204-10. PubMed ID: 18951507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
    Kholodilov NG; Neystat M; Oo TF; Lo SE; Larsen KE; Sulzer D; Burke RE
    J Neurochem; 1999 Dec; 73(6):2586-99. PubMed ID: 10582622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
    Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
    Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease.
    Büttner S; Habernig L; Broeskamp F; Ruli D; Vögtle FN; Vlachos M; Macchi F; Küttner V; Carmona-Gutierrez D; Eisenberg T; Ring J; Markaki M; Taskin AA; Benke S; Ruckenstuhl C; Braun R; Van den Haute C; Bammens T; van der Perren A; Fröhlich KU; Winderickx J; Kroemer G; Baekelandt V; Tavernarakis N; Kovacs GG; Dengjel J; Meisinger C; Sigrist SJ; Madeo F
    EMBO J; 2013 Nov; 32(23):3041-54. PubMed ID: 24129513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.
    Michell AW; Tofaris GK; Gossage H; Tyers P; Spillantini MG; Barker RA
    Cell Transplant; 2007; 16(5):461-74. PubMed ID: 17708336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
    Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
    Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.